Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.
相关临床试验
11
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2017
进行中（未招募）
6
54.5%
已完成
1
9.1%
招募中
1
9.1%
终止
3
27.3%
暂无批准数据
- Ignota Labs acquired Kronos Bio's entire clinical pipeline, including CDK9 inhibitor istisociclib and SYK inhibitors entospletinib and lanraplenib, after the company ceased operations despite a peak valuation of $3.5 billion. - The acquisition targets blood cancers and autoimmune disorders representing significant market opportunities, with chronic lymphocytic leukemia valued at $8 billion globally and immune thrombocytopenia purpura at $1.5 billion. - Ignota's AI platform SAFEPATH will analyze the root causes of toxicity issues that led to the drugs' failure, aiming to solve safety problems while maintaining therapeutic effectiveness. - The deal was facilitated through Concentra Biosciences, which acquired Kronos for approximately $35 million and transferred the assets to Ignota for an undisclosed upfront fee plus milestone payments.
- Cargo Therapeutics agreed to be acquired by Concentra Biosciences for approximately $202 million upfront after halting development of its lead CAR-T therapy firicabtagene autoleucel due to poor durability results. - The company's Phase II trial showed firi-cel achieved a 77% response rate but only 18% durability at three months, leading to rapid patient relapse and termination of the mid-stage study in January. - Concentra, backed by Tang Capital Partners, continues its acquisition strategy targeting distressed biotechs, having completed five buyouts in 2024 including Elevation Oncology and Kronos Bio. - The deal provides Cargo shareholders with 100% of net cash above $217.5 million at closing plus 80% of proceeds from asset sales within two years, effectively winding down the company that raised $200 million in 2023.
- Elevation Oncology has agreed to be acquired by Concentra Biosciences, controlled by hedge fund Tang Capital Partners, for $0.36 per share in cash with additional contingent value rights. - The acquisition represents the latest example of investment firms targeting struggling biotech "zombies" worth less than their cash reserves for liquidation rather than strategic repositioning. - Elevation's lead cancer drug disappointed in clinical testing, forcing the company to shelve its program, lay off most staff, and trade below $1 per share for nearly a year. - The deal follows Tang Capital's previous acquisitions of struggling biotechs including Allakos, Jounce Therapeutics, and Kronos Bio through its liquidation-focused investment strategy.
- Concentra Biosciences has entered into definitive merger agreements to acquire both iTeos Therapeutics for $10.047 per share and Kronos Bio for $0.57 per share, with both deals including contingent value rights. - The iTeos acquisition includes a CVR providing 100% of closing net cash above $475 million and 80% of proceeds from product candidate dispositions within six months post-closing. - Both transactions are expected to close in 2025, with iTeos closing anticipated in Q3 and Kronos Bio mid-year, subject to tender offer conditions and regulatory approvals. - The deals represent a strategic consolidation in the biotech sector, with Concentra acquiring complementary assets in oncology and immunotherapy development.
• Kronos Bio discontinued istisociclib (KB-0742) development after safety concerns arose in a Phase I/II trial for platinum-resistant high-grade serous ovarian cancer. • The trial revealed neurological adverse events in five of seven patients, leading to treatment discontinuation or dosage reduction in some participants. • Facing financial pressures, Kronos Bio is exploring strategic alternatives, including acquisition or merger, to maximize stockholder value and preserve cash. • The company is also seeking partnerships for preclinical assets KB-9558 and KB-7898, while focusing on IND application for multiple myeloma and autoimmune disorders.
• Kronos Bio has nominated KB-7898, a p300 KAT inhibitor, as its first development candidate for autoimmune diseases, specifically targeting Sjögren's disease. • KB-7898, designed as an oral therapy, aims to modulate immune responses by inhibiting p300's cofactor role in interferon regulatory factor 4 (IRF4) activity. • Preclinical data, to be presented at ACR Convergence 2024, demonstrates KB-7898's ability to reduce antibody production in B cells and cytokine production in T cells. • IND-enabling studies for KB-7898 are planned for Q4 2024, addressing the unmet need for treatments targeting the underlying cause of Sjögren's disease.
